Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMIL Study
2024-513410-35-00Phase 3Authorised
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in subarachnoid hemorrhage (SAH) comparing Milrinone with Placebo (2 arms). Primary endpoint: Volume of delayed cerebral ischemia (DCI) lesions on CT at 1 month. Planned start Sep 2024; status: authorised.
02
Drugs
milrinone
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on 2024-513410-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513410-35-00.